Notably, in cytotoxicity assays against primary B-ALL blasts, CAT/9A8 and 9A8 cytotoxicity was reduced against CD19–/CD22+ B-ALL compared with a double-positive patient sample. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.